Filtered By:
Drug: Eloxatin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 7 results found since Jan 2013.
LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases —a phase II study
ConclusionsPanitumumab and FOLFIRI as perioperative therapy for resectable CLM result in a radiological objective response rate in 65.7% of patients with a manageable grade 3 diarrhea rate of 14.3%. Median PFS was 13.2 months, and the 24-month OS rate was 73.3%. These data are insufficient to widen the indication of panitumumab from the unresectable setting to the setting of resectable CLM.
Source: Frontiers in Oncology - August 9, 2023 Category: Cancer & Oncology Source Type: research
Design and synthesis of the first indole-based blockers of Panx-1 channel
We present here a study aimed at obtaining the first class of selective Panx-1 blockers, a new topic for pharmaceutical chemistry, since all compounds used so far for the study of this channel have different primary targets. Among various scaffolds analyzed, the indole nucleous emerged, whose elaboration yielded interesting Panx-1 blockers, such as the potent 5-sulfamoyl derivatives 14c and 15b (I% = 100 at 50 μM). In vivo tests performed in the mouse model of oxaliplatin-induced neuropathy, demonstrated that the hypersensitivity was completely reverted by treatment with 15b (1 nmol, administered intrathecally), suggestin...
Source: European Journal of Medicinal Chemistry - June 26, 2021 Category: Chemistry Authors: Letizia Crocetti Gabriella Guerrini Sara Puglioli Maria Paola Giovannoni Lorenzo Di Cesare Mannelli Elena Lucarini Carla Ghelardini Junjie Wang Gerhard Dahl Source Type: research
Role of TREK-1 in Health and Disease, Focus on the Central Nervous System
Conclusion and Perspectives
Since their cloning 20 years ago, the physiological importance of TREK-1 channels has continued to grow (Figure 3). Today, TREK-1 channels have been shown to be important and their presence is essential in a number of physiopathological processes. Their involvement in these different processes demonstrate the necessity to design pharmacological modulators, activators or inhibitors, of these channels to correct any TREK-1-related dysfunctions.
Despites a number of studies and many molecule screenings, only few putative new drugs were identified. The activators belonging to the ML and BL series ...
Source: Frontiers in Pharmacology - April 10, 2019 Category: Drugs & Pharmacology Source Type: research
Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first ‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.
In this study, we evaluated the effects of aflibercept in first‑line therapy with FOLFOX followed by maintenance with fluoropyrimidine. VELVET was a prospective, single‑arm multicenter phase II study (completed). Patients with previously untreated, unresectable, evaluable or measurable mCRC, with an age ≥18 years, and an ECOG performance status of 0‑2 received 6 cycles of modified FOLFOX7 (5‑FU/folinic acid and oxaliplatin) with aflibercept at 4 mg/kg every 2 weeks followed by maintenance therapy with fluoropyrimidine with aflibercept until disease progression or limiting toxicity. The reintroduction of oxa...
Source: International Journal of Oncology - February 1, 2019 Category: Cancer & Oncology Authors: Chibaudel B, Bachet JB, André T, Auby D, Desramé J, Deplanque G, Lecaille C, Louvet C, Tournigand C, Lebrun-Ly V, Dauba J, Lledo G, Garcia ML, Dubreuil O, Hamed NB, Meurisse A, Larsen AK, Tijeras-Raballand A, Bonnetain F, De Gramont A Tags: Int J Oncol Source Type: research
Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy
Stroke mimics, especially those involving chemotherapy related neurotoxicity, can confound the clinical diagnosis of acute stroke. Here we describe the case of a 63year-old male with a recent history of stage IIIC colon cancer who presented with confusion on the second day of modified FOLFOX6 (5-fluorouracil/oxaliplatin) chemotherapy and subsequently received alteplase, tissue plasminogen activator therapy (tPA), for presumed ischemic stroke. Magnetic resonance imaging scans after tPA administration did not reveal evidence of an infarction and the patients' neurological symptoms resolved completely after discontinuation of...
Source: The American Journal of Emergency Medicine - July 6, 2017 Category: Emergency Medicine Authors: May Thuy Nguyen, Robyn Stoianovici, Luigi Brunetti Source Type: research
Chemotherapy-induced peripheral neuropathy: the end of the beginning?
From the clinician's perspective, the study signifies an important step in enabling effective treatment strategies Rapid advances have been made in the diagnosis and treatment of neurological disease over the last two decades. Over that period, major developments have also occurred in other fields of medicine, most notably in the management of cancer. Two-thirds of all cancer patients now survive at 5-years post-diagnosis, with over 28 million cancer survivors worldwide.1 As cancer outcomes improve, there has been increased focus on the long-term quality of life in cancer survivors. Not unexpectedly, neurological complicat...
Source: Journal of Neurology, Neurosurgery and Psychiatry - March 5, 2014 Category: Neurosurgery Authors: Krishnan, A. V., Park, S. B. Tags: Neuromuscular disease, Peripheral nerve disease, Stroke Editorial commentaries Source Type: research
